Phylogica Limited

ASX:PYC ISIN:AU000000PYC7

Phylogica Limited (Phylogica) is an Australia-based company principally engaged in the discovery and development of therapeutics directed at proteins and their interactions. The Company is engaged in the discovery of peptide-based drugs to treat inflammatory diseases.  
 
        

查看其它語言版本

新聞

2010年12月20日澳洲股市:IMX Resources (ASX:IXR)首批鐵銅礦石船運貨物發往中國

🕔12/20/2010 1:30:00 PM 11729

2010年12月20日澳洲股市:IMX Resources (ASX:IXR)已向中國發運第一批鐵銅礦石貨物;澳洲藥品開發公司Phylogica Limited (ASX:PYC)已與輝瑞製藥(NYSE:PFE)簽訂合作與許可證協議;Copper Strike Limited (ASX:CSE)在昆士蘭西北部的Walford Creek項目已取得良好的銅/銀/鈷結果;South American Ferro Metals Limited (ASX:SFZ)在巴西生產的鐵礦石超出400,000噸。

閱讀全文
###

85,904 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 19) (過去30日: 119) (自發布以來: 9429) 

公司詳細

    傳真
  • 08 9423 8899 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.phylogica.com/

更多新聞紀錄

  • 2024/11/01: First ADOA Patient Dosed in Clinical Trial*
  • 2024/10/31: Presentation of RP11 Single Dose Data at RANZCO*
  • 2024/10/25: Quarterly Activities/Appendix 4C Cash Flow Report*
  • 2024/10/22: Interim Update on Progress in RP11 Repeat Dose Trials*
  • 2024/10/21: Trading Halt*
  • 2024/10/21: US FDA Grants Orphan Drug Designation to PYC Drug Candidate*
  • 2024/10/14: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/09: 2024 Corporate Governance Statement & Appendix 4G*
  • 2024/10/09: Annual Report to shareholders*
  • 2024/09/26: E&P Healthcare Conference Presentation*
*refer to company website